A Phase 1b Trial of Hu5F9-G4 in Combination With Avelumab in Solid Tumor Patients and Checkpoint-Inhibitor-Naive Ovarian Cancer Patients Who Progress Within 6 Months of Prior Platinum Chemotherapy
Latest Information Update: 03 Apr 2024
At a glance
- Drugs Avelumab (Primary) ; Magrolimab (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Forty Seven; Gilead Sciences
- 17 Dec 2020 Status changed from active, no longer recruiting to completed.
- 16 Oct 2020 Planned End Date changed from 1 May 2023 to 1 Dec 2020.
- 16 Oct 2020 Planned primary completion date changed from 31 Jul 2020 to 1 Nov 2020.